Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Stock Information for Ravelin Properties REIT

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ravelin Properties REIT

Fennec Announces Results of Annual Meeting
Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.